Nausea And Vomiting - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 93

Nausea And Vomiting - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Nausea And Vomiting Pipeline Review, Q4 2010”, provides an overview of the Nausea And Vomiting therapeutic pipeline. This report provides information on the therapeutic development for Nausea And Vomiting , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nausea And Vomiting . “Nausea And Vomiting -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Nausea And Vomiting   .
- A review of the Nausea And Vomiting    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nausea And Vomiting    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Nausea And Vomiting   .
- A review of the Nausea And Vomiting    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nausea And Vomiting    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nausea And Vomiting Overview
Therapeutics Development
An Overview of Pipeline Products for Nausea And Vomiting
Nausea And Vomiting Therapeutics under Development by Companies
Nausea And Vomiting Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Nausea And Vomiting Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
A.P. Pharma, Inc.
Archimedes Pharma Limited
Aphios Corporation
Astellas Pharma Inc.
Ono Pharmaceutical Co., Ltd.
ProStrakan Group plc
Teikoku Pharma USA, Inc.
Eisai Inc.
Dharma Therapeutics, Inc.
Simbec Research Ltd
Victory Pharma, Inc.
Ikano Therapeutics, Inc.
PepTcell Limited
Acacia Pharma Ltd.
Universities/Institutes Involved in Nausea And Vomiting Therapeutics Development
Nausea And Vomiting Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
AB-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APF530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APF530 + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant dimeglumine + Ondansetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lerisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGX006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PALO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proemend - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramosetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zindol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant + Palonosetron + Dexamethasone for Nausea and Vomiting - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carbidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyproheptadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethason + Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Dronabinol + Palonosetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Granisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emend - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant dimeglumine + Dexamethasone + Palonosetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone + Prochlorperazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Haloperidol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mephameson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramosetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Nausea And Vomiting - Featured News
Sep 06, 2010: Acacia Pharma To Progress Two Projects For Nausea & Vomiting And Xerostomia Into Clinical Development
Jun 02, 2010: Merck Announced Results From Non-Inferiority Trial Of Fosaprepitant Dimeglumine And dexamethasone For Prevention Of Chemotherapy-Induced Nausea and Vomiting
Mar 25, 2010: SciClone Announces EU Approval For Ondansetron RapidFilm
Mar 23, 2010: BioDelivery Sciences Announces Positive Pre-IND Meeting On BEMA Granisetron Development Program
Mar 22, 2010: A.P. Pharma Receives FDA Complete Response Letter For APF530
Mar 15, 2010: Tranzyme's Clinical Results On Ulimorelin Selected For Oral Presentation At Digestive Disease Week 2010
Jul 20, 2009: A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting
Jul 20, 2009: FDA Accepts NDA For APF530 For Chemotherapy-Induced Nausea And Vomiting (CINV)
May 18, 2009: A.P. Pharma Submits New Drug Application For APF530 In Chemotherapy-Induced Nausea and Vomiting
Oct 01, 2008: A.P. Pharma Announces Positive Phase 3 Results With APF530 In The Prevention Of Chemotherapy Induced Nausea And Vomiting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Post Operative Nausea And Vomiting – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013